Preliminary data indicate the presence of inflammatory derangements in AML, necessitating a comprehensive examination of inflammatory effector cytokines involved in AML pathogenesis and therapeutic responses. Addressing this issue requires overcoming two major challenges: the existence of over 300 cytokines associated with human disease, and the presence of functional yet low-level cytokines. A high-throughput method capable of characterizing numerous cytokines and identifying potential therapeutic targets is essential, along with a cytokine profiler that captures a wide dynamic level range. We propose utilizing NULISA, a novel method that enables the comprehensive characterization of more than 200 important cytokines and chemokines with ultra-high sensitivity and scalable multiplexing, effectively tackling both challenges. 88 Serum samples from AML and healthy subjects were profiled using Alamar’s NULISAseq 200-plex Inflammation panel. Unsupervised clustering showed different sample groups clustering together and differential expression analysis revealed unique inflammation profiles for AML patients compared to healthy donors. These results revealed that 200-plex Inflammation panel can detect various circulatory inflammatory biomarkers with high sensitivity and specificity and these features can reveal novel biological insights into inflammatory derangements in AML disease.